A randomized, double-blind, placebo-controlled clinical trial to investigate the effect of Cynatine® FLX on symptoms of osteoarthritis.
OBJECTIVE
A novel product Cynatine® FLX was evaluated on symptoms associated with knee osteoarthritis in a randomized, double-blind, placebo-controlled clinical trial.


METHODS
A total of 50 males and females were included and randomized into two groups. The active group (n = 25) received two capsules totaling 500 mg of Cynatine® FLX per day and the placebo group (n = 25) received an identical two capsules of maltodextrin per day for 60 days. The WOMAC® Osteoarthritis Index, SF-36, and Lequesne Index of Severity were used to evaluate the symptoms.


RESULTS
The results show that Cynatine® FLX was twice as effective in reducing pain scores as compared to placebo. Cynatine® FLX showed the same effectiveness in reducing stiffness.


CONCLUSIONS
This new product may be effective in relieving symptoms of knee osteoarthritis.
CB Food Consulting LLC, Salt Lake City, UT 84115, USA.
Christina
C
Beer
Simon
S
Wood
Robert H
RH
Veghte
D000328:Adult; D000368:Aged; D000818:Animals; D001688:Biological Products / Q000494:pharmacology / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007633:Keratins / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D059352:Musculoskeletal Pain / Q000188:drug therapy* / Q000209:etiology; D020370:Osteoarthritis, Knee / Q000150:complications / Q000188:drug therapy*; D016059:Range of Motion, Articular / Q000187:drug effects; D012720:Severity of Illness Index; D012756:Sheep; D014935:Wool / Q000737:chemistry
D001688:Biological Products; D007633:Keratins